Abstract
Lung cancer is one of the leading causes of cancer deaths in the developed world. It is grossly divided into small cell and nonsmall cell types. Depending on the stage at diagnosis, the principal means of treating nonsmall cell lung cancer are surgery, chemotherapy and/or radiotherapy. However, even when it is diagnosed at an early stage, the progression-free and overall survival rates have been disappointing compared with other cancers. In recent years, there have been a number of developments in the chemotherapeutic options for nonsmall cell lung cancer. The aim of this review is to summarize these developments, in a stage-specific manner, with respect to both standard chemotherapy and also the newer targeted therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
